Belgian Biotech Novadip Raises $12M to Fast-Track Bone Healing Trial

Jan de Vries · 2026-09-21

### A Strong Vote of Confidence Novadip Biosciences, a Belgian late-stage clinical biotech company specializing in regenerative medicine, has just closed a €10.4 million (roughly $12 million) convertible financing round. The round was led by US-based New Science Ventures, with participation from existing backers including Fund+, Wallonie Entreprendre, VIVES Fund, ORSA Tech, Sambrinvest, Noshaq, and Invest.BW. This brings the total convertible financing since June 2025 to €20 million, following a €9.6 million convertible loan last year. "This financing is a strong vote of confidence from our investors, and I’d like to thank them for their ongoing support," said Dr. Denis Dufrane, founder and CEO of Novadip. "It provides the resources to advance NVD003 through several major clinical and regulatory milestones, including the completion of our pivotal Phase 3 program in congenital pseudarthrosis of the tibia and the preparation for regulatory submission in the United States." ### What Novadip Does Founded in 2013 as a spin-off from Université Catholique de Louvain and St. Luc University Hospital, Novadip has developed a proprietary platform called 3M³. This technology uses adipose-derived stem cells arranged within a three-dimensional extracellular matrix to create tissue capable of healing large bone defects, non-union fractures, and spinal fusion cases in a single procedure. The company's pipeline is built on two candidates: NVD003 and NVDX3. NVD003, the focus of this financing round, is a moldable, autologous graft made from a patient's own stem cells, designed to be implanted within three months of cell collection. It has already shown durable bone fusion at 24 months and maintained mobility up to four-year follow-up. NVDX3, an allogenic bone grafting material, has completed Phase 1b/2a trials in trauma surgery and spinal fusion and has FDA clearance to begin a Phase 2b/3 trial. ### The Road Ahead The new funds will primarily support the completion of a pivotal Phase 3 trial of NVD003 for congenital pseudarthrosis of the tibia (CPT), a rare and difficult-to-treat pediatric bone condition. The trial is already running in both the United States and the European Union. The funds will also cover preparation of a Biologics License Application (BLA) to the US Food and Drug Administration, and support the company's push toward value-creating milestones, including potential strategic partnerships and, if the BLA is approved, a Rare Pediatric Disease Priority Review Voucher from the FDA, which the company values at more than $100 million. "With a pivotal Phase 3 program underway, regulatory preparation advancing, and a significant commercial opportunity, Novadip is entering a critical value-creating period," said Eric Pâques, Chairman of the Board. "This financing provides the means to execute on these priorities and prepare the business for its next stage of development." ### Timeline and Impact Novadip is aiming to obtain market authorization for NVD003 in congenital pseudarthrosis of the tibia by 2028, followed by approval for adults with critical-size bone defects by 2031. Hitting the €10.4 million target also opens access to a tranche of an €18 million venture debt agreement Novadip signed in 2023 with the European Investment Bank, backed by the European Union's InvestEU programme. The company now employs 53 people and has raised €137 million in equity and non-dilutive funding since inception. This financing round not only fuels Novadip's clinical trials but also signals growing investor confidence in European biotech innovation. As the company advances its pipeline, it could bring new hope to patients suffering from rare bone conditions.